Jun 5, 2020
MediSieve Selected for the London & Partners’ Business Growth Programme
MediSieve was accepted onto the London & Partners’ Business Growth Programme.
LONDON – June 05, 2020 – MediSieve was accepted onto the London & Partners’ Business Growth Programme. The free, three-month programme is giving London-based companies the tools they need to survive and thrive during these challenging times - from mentorship and account management, to expert advice and new business opportunities.
Dr George Frodsham, founder and CEO of MediSieve, said: "We are very pleased to be chosen for this competitive programme, which will provide us with great opportunities for further development. As a young company, we understand the importance of supplementing our scientific knowledge with the ability to evaluate the best business growth strategies. The timing is really good for us, as we are currently undergoing a lot of changes after we have decided to expand our research into the treatment of COVID-19. We are thankful to be selected and are looking forward to learning from the programme and other bright participants!"
The three-month programme consists of:
A business growth adviser: dedicated advice and guidance including a tailored growth plan
Corporate engagement: collaborate with larger corporates with operations in London
Workshops and events: opportunities to learn from expert advisers and peers
Mentoring scheme: expert help and advice from those who have experienced it first-hand
Local business support: introduction to a full range of London & Partners' service providers
Companies join the programme in cohorts, having a unique opportunity to collaborate and share knowledge with the industry's bright minds. After a detailed review of our application, London & Partners offered MediSieve a place in the Summer Cohort, which will be launched on 23 June.
Learn more about the programme: https://business.london/business-growth-programme/about?ref=nav
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: